Tevimbra Dosage

Generic name: TISLELIZUMAB 10mg in 1mL
Dosage form: injection, solution, concentrate
Drug class: Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)

Medically reviewed by Drugs.com. Last updated on May 5, 2025.

Patient Selection

Select patients for the first-line treatment of unresectable or metastatic esophageal squamous cell carcinoma based on the presence of PD-L1 in tumor specimens. An FDA-approved companion diagnostic for the detection of PD-L1 in patients with unresectable or metastatic esophageal squamous cell carcinoma is not available.

Select patients for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) based on the presence of PD-L1 in tumor specimens. An FDA-approved companion diagnostic for the detection of PD-L1 in patients with unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) is not available.

Recommended Dosage

The recommended dosages of TEVIMBRA administered intravenously as a single agent or in combination with other therapeutic agents are presented in Table 1.

Table 1: Recommended Dosages for TEVIMBRA as a Single Agent or in Combination with Other Therapeutic Agents
Indication	Recommended Dosage of TEVIMBRA	Duration/Timing of Treatment
ESCC OR First-Line Gastric Cancer	150 mg every 2 weeks OR 200 mg every 3 weeks OR 300 mg every 4 weeks	Until disease progression or unacceptable toxicity.

Refer to the respective Prescribing Information for each therapeutic agent administered in combination with TEVIMBRA for the recommended dosage information, as appropriate.

Dosage Modifications for Adverse Reactions

No dose reduction of TEVIMBRA is recommended. In general, withhold TEVIMBRA for severe (Grade 3) immune-mediated adverse reactions. Permanently discontinue TEVIMBRA for life-threatening (Grade 4) immune-mediated adverse reactions, recurrent severe (Grade 3) immune-mediated reactions that require systemic immunosuppressive treatment, or an inability to reduce corticosteroid dose to 10 mg or less of prednisone equivalent per day within 12 weeks of initiating steroids.

Dosage modifications for TEVIMBRA for adverse reactions that require management different from these general guidelines are summarized in Table 2.

Refer to the respective Prescribing Information for dosage modifications for the platinum and fluoropyrimidine agent administered in combination with TEVIMBRA.

Table 2: Recommended Dosage Modifications for Adverse Reactions
Adverse Reaction	Severity of Adverse Reaction*	Dosage Modifications
ALT = alanine aminotransferase, AST = aspartate aminotransferase, ULN = upper limit of normal, SJS = Stevens-Johnson syndrome, TEN = toxic epidermal necrolysis, DRESS = drug rash with eosinophilia and systemic symptoms.
* Based on Common Terminology Criteria for Adverse Events (CTCAE) Version 4. † Resume in patients with complete or partial resolution (Grades 0 to 1) after corticosteroid taper. Permanently discontinue if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to 10 mg per day or less (or equivalent) within 12 weeks of initiating steroids. ‡ If AST and ALT are less than or equal to ULN at baseline, withhold or permanently discontinue TEVIMBRA based on recommendations for hepatitis with no liver involvement. § Resume infusion if resolved or decreased to Grade 1, and slow rate of infusion by 50% of the previous rate.
Immune-Mediated Adverse Reactions
Pneumonitis	Grade 2	Withhold†
Pneumonitis	Grade 3 or 4 or recurrent Grade 2	Permanently discontinue
Colitis	Grade 2 or 3	Withhold†
Colitis	Grade 4	Permanently discontinue
Hepatitis with no tumor involvement of the liver	AST or ALT increases to more than 3 and up to 8 times ULN or Total bilirubin increases to more than 1.5 and up to 3 times ULN	Withhold†
Hepatitis with no tumor involvement of the liver	AST or ALT increases to more than 8 times ULN or Total bilirubin increases to more than 3 times ULN	Permanently discontinue
Hepatitis with tumor involvement of the liver‡	Baseline AST or ALT is more than 1 and up to 3 times ULN and increases to more than 5 and up to 10 times ULN or Baseline AST or ALT is more than 3 and up to 5 times ULN and increases to more than 8 and up to 10 times ULN	Withhold†
Hepatitis with tumor involvement of the liver‡	ALT or AST increases to more than 10 times ULN or Total bilirubin increases to more than 3 times ULN	Permanently discontinue
Endocrinopathies	Grade 3 or 4	Withhold until clinically stable or permanently discontinue depending on severity
Nephritis with renal dysfunction	Grade 2 or 3 increased blood creatinine	Withhold†
Nephritis with renal dysfunction	Grade 4 increased blood creatinine	Permanently discontinue
Exfoliative dermatologic conditions	Grade 3, or suspected SJS, TEN, or DRESS	Withhold†
Exfoliative dermatologic conditions	Grade 4, or confirmed SJS, TEN, or DRESS	Permanently discontinue
Myocarditis	Grade 2, 3, or 4	Permanently discontinue
Neurological toxicities	Grade 2	Withhold†
Neurological toxicities	Grade 3 or 4	Permanently discontinue
Other Adverse Reactions
Infusion-related reactions	Grade 1	Slow infusion rate by 50%
Infusion-related reactions	Grade 2	Interrupt infusion§
	Grade 3 or 4	Permanently discontinue

Preparation and Administration

Preparation

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. TEVIMBRA is a clear to slightly opalescent, colorless to slightly yellow solution. Discard the vial if the solution is cloudy, discolored, or contains visible particles. Do not shake the vial.

Prepare the solution for infusion as follows:

Withdraw the required volume of TEVIMBRA from the vial(s).
Transfer solution into an intravenous infusion bag containing 0.9% Sodium Chloride Injection, USP to prepare an infusion solution with a final concentration of 2 mg/mL to 5 mg/mL.
Mix diluted solution by gentle inversion to avoid foaming or excessive shearing of the solution. Do not shake.
TEVIMBRA is for single use only. Discard any unused portion left in the vial.

Storage of Diluted Solution

This product does not contain any preservatives. If not used immediately, store the TEVIMBRA diluted solution either:

At room temperature at 20°C to 25°C (68°F to 77°F) for up to 4 hours, including preparation and infusion duration. Discard after 4 hours.
Under refrigeration at 2°C to 8°C (36°F to 46°F) for up to 20 hours, including preparation and infusion duration. Allow the diluted solution to come to room temperature prior to administration. Discard after 20 hours.

Do not freeze the diluted solution.

Administration

Administer diluted solution by intravenous infusion through an intravenous line with a sterile, nonpyrogenic, low protein binding 0.2 micron or 0.22 micron in-line or add-on filter.
For 150 mg and 200 mg doses, administer the initial infusion over 60 minutes. If tolerated, all subsequent infusions may be administered over 30 minutes.
For 300 mg doses, administer the initial infusion over 90 minutes. If tolerated, administer the second infusion over 60 minutes. If the second infusion is tolerated, administer subsequent infusions over 30 minutes.
Do NOT coadminister other drugs through the same infusion line.
Do NOT administer TEVIMBRA as an intravenous push or single bolus injection.
Flush the intravenous line at the end of infusion.

More about Tevimbra (tislelizumab)

Patient resources

Tevimbra drug information

Professional resources

Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Drug Status

Availability Prescription only Rx

Pregnancy & Lactation Risk data available

CSA Schedule* Not a controlled drug N/A

Approval History Drug history at FDA

User Reviews & Ratings

Review this drug

Tevimbra Dosage

Patient Selection

Recommended Dosage

Dosage Modifications for Adverse Reactions

Preparation and Administration

More about Tevimbra (tislelizumab)

Patient resources

Professional resources

Related treatment guides

See also:

Keytruda

Xeloda

Opdivo Qvantig

Herceptin

Opdivo

Enhertu

Taxotere

Lonsurf

Trazimera

Ogivri

Further information